Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fermented brown rice (Aspergillus oryzae), commonly referred to as FBRA, is a functional food supplement and prebiotic developed by Genmai-Koso Co. Ltd. in Japan. It is produced by the fermentation of brown rice and rice bran using the fungus *Aspergillus oryzae*. FBRA is rich in dietary fiber and various bioactive metabolites generated during the fermentation process. It has been extensively studied for its potential chemopreventive and anti-inflammatory properties. The mechanism of action involves the suppression of inflammatory cell infiltration and the down-regulation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), Mac-1, CCL3, and CXCL2. Additionally, FBRA has been shown to induce apoptosis in cancer cells through both death receptor and mitochondrial pathways. Research has demonstrated its ability to inhibit tumorigenesis in various models, including pancreatic, colorectal, bladder, and oral cancers, and it has also been investigated for potential benefits in type 1 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fermented brown rice (Aspergillus oryzae).